Stem cell bank gets harvesting equipment

November 30, 2009

Courtesy by: expressbuzz.com

CHENNAI: A city-based stem cell bank on Wednesday urged the Rotary Foundation to add stem cells to the bouquet of projects it runs at the national level. Dr Saranya Narayan, co-founder and medical director of Jeevan Blood Bank and Research Centre, made the request after receiving a stem cell harvesting equipment that was donated by the Rotary Club of Madras East, along with RI District 3230, Rotary Foundation and Rotary Club of Makati Ayala. The equipment, costing about Rs 25 lakh, will be used to recover stem cells from cord blood donated to Jeevan’s stem cell bank.

With 42,000 registered childbirths everyday, India can contribute substantially towards the cure of blood and blood-related diseases through stem cells, Dr Narayan said. Stem cells, she said, could be used to treat both thalassemia and leukemia.

Speaking on the club’s anti-polio efforts, Rotarian W Anand, governor, RI District 3230, said the disease could be eradicated in India in three years, with efforts by both the Rotary Foundation and the Indian government.

Recalling the Rotary Foundation’s global role in the eradication of polio, Anand said serious efforts should be made to make India polio-free.


B+ve to A+ve, he beats thalassemia

November 22, 2009

Courtesy by: timesofindia

AHMEDABAD: Exactly 49 days ago, Harshil Nanda was a severely ill thalassemic patient with B positive blood group. Today, he is a healthy infant with A positive blood group and a confirmed evidence of how stem cell transplant can cure thalassemia.

The change in his blood group is in fact proof that Harshil’s procedure, the country’s second stem cell transplant from umbilical cord blood of a stranger child received from a private bank, has worked.

Harshil’s rapid recovery has cheered stem cell transplant surgeons at Gujarat Cancer Research Institute (GCRI) where the first such transplant was performed nearly a year ago.

“This means that unrelated umbilical stem cell transplant can be termed as an established treatment. As they say, first success could be luck but second is science,” said director of bone marrow transplant department at GCRI Dr Sandip A Shah. The transplant was assisted by Dr Kinnari Patel and Dr Kamlesh Shah.

The first success story was of Rishi, a thalassemic major child from Kutch, who was cured by umbilical cord stem cells transplanted from an unrelated donor as he did not have siblings. Harshil is also the only child of his parents.

“While it took three months in Rishi for the donor blood cells to completely take over and change his blood group, Harshil has recovered within two months,” said Dr Shah.

For children without siblings and suffering from thalassemia, aplastic anaemia and similar blood problems, this is good news. The success rate of such transplants is 70 per cent.

Doctors are now poised to perform a third unrelated umbilical cord stem cell transplant. “The third patient is a girl called Zeel, who has got Rs 10 lakh as donation from Bollywood star Ajay Devgan to perform the transplant,” said Dr Shah.


Cryobanks to step up awareness on stem cell banking

November 12, 2009

Courtesy by: business-standard.com

Cryobanks International India, a leader in umbilical cord blood stem cell banking, aims to expand its network in Orissa by involving more families in the state for storage of umbilical cord blood.

Around 200 families in the state have stored umbilical cord blood so far and the company expects this number to grow as it has lined up awareness programmes on this concept in different parts of Orissa.

Phagun Shah, medical advisor, Cryobanks International India said, “The people of Orissa have shown very keen interest in the concept of umbilical cord blood banking and hence we have seen fast growth in 2008. We look forward to developing more awareness on this subject in different parts of the state and expect more enrolments in 2009-10.”

“The umbilical cord blood is a rich source of stem cells and the bank will store them from any willing family for a certain fee. These cells will be vital in saving the life of a person suffering from leukemia, thalassemia, blood cancer and bone marrow transplant”, added Shah.

The people who opt for umbilical cord blood stem cell banking would have to pay Rs 75,000 for a storage duration of 21 years. The amount can be paid either upfront or through equated monthly installments (EMIs).

Cord blood banking is a process of preserving extra blood in the umbilical cord that is attached from the mother’s womb to the baby. The blood in the umbilical cord is rich in stem cells that can be restored and replenished for future use of the baby and his immediate family.

Ghazi Aasim, marketing head, Cryobanks International India said, “With the availability of cord stem cells, one is free from the hassle of arranging a matching bone marrow donor.


Cord blood stem cell transplantation cures minor girl

September 16, 2009

Courtesy by: samaylive

Chennai, Sept 16 An eight-year-old girl suffering from Thalassemia has been cured by ‘cord blood stem cell transplantation’ at a hospital here.

The doctors used her younger brother’s cord blood stem cells for transplantation and the hospital authorities claimed it was the first time this method was practised.

Thalassemia is a genetic blood disorder in which the body makes an abnormal form of hemoglobin that results in excessive destruction of these cells and causes severe anaemia that can occur months after the birth. The patient then has to undergo monthly blood transfusion.

Mayur Abhaya, president and executive director of LifeCell International, a leading stem cell bank, told reporters here that Thamirabhurani was suffering from Thalassemia for the last six and a half years.

She went through painful blood transfusion and medication until the stem cell Cord blood stem cell transplantation cures minor girl, he said.

“The stem cell transplantation was recently done by Dr Revathi Raj at Apollo Hospital and it helped the girl get rid of Thalassemia,” he said, adding doctors had recommended that the patient start on iron reducing medication initially.

“The doctors then asked her parents to consider another pregnancy and go for umbilical cord blood stem cell banking”, he added.

Raj said a pre-natal test confirmed that the foetus was not affected with Thalaseemia.


Stem cell bank to start in July next year

September 16, 2009

Courtesy by: thepeninsulaqatar

DOHA: Bringing renewed hope in the treatment of various medical conditions in the Eastern Mediterranean region, the Virgin Health Bank (VHB)-QSTP, will start its operations here in July 2010. The bank which collects, processes and stores cord blood, taken from the umbilical cord of newborns, was launched here in March as a partnership between Qatar Science and Technology Park (QSTP) and the UK-based VHB.

With the bank headquarters opening here, Qatar will be at the forefront of using regenerative medicine.

“We aim to transform lives through the use of cord blood stem cells in the region. This will be by providing information and championing new standards of high quality ethical banking services,” said Andrew Glen, Commercial Director, VHB-QSTP.

The stem cells, taken from the blood in the umbilical cord, can renew themselves through cell division and differentiating into specialised cell types. Today, 85 diseases can be treated using cord blood. Sickle cell anemia and thalassemia can be completely cured using cell therapy. The facility opening here will help spur cell therapy for various disorders including genetic ones.

“The bank will open as a private one, where families can pay to store the cord blood. This is the major step before venturing into public banking which can ensure that the blood stored can be utilised for community needs. Talks are in progress for public banking.”

When public banking starts, VHB-QSTP will play a major role in Qatar’s much coveted national public health programme to create the world’s first comprehensive source of stem cells for the Middle Eastern population and make it easier to source a matched tissue typed stem cell unit when a transplant is needed.

The VHB project has already commenced in Qatar as a pilot programme with over a dozen cord blood samples being cryogenically stored in the UK. “With the cooperation of Ministry of Interior and Qatar Airways, we have been able to study the various issues in transportation of the samples to UK. To get the best result out of the cells, every thing from collecting to temperature and transportation time matters,” said Dr Magnus Nicolson.

However, by 2010, the bank will have a storage and processing unit in Qatar.

The VHB presence here will catalyse the national health programme which calls for a public bank, as people will get to know the benefits.

The bank has been conducting training for health professionals in Qatar on the management, collection and preservation of the cord blood as part of the public health programme.


Need to tap potential of wonder stem cells

September 16, 2009

Courtesy by: timesofindia

VARANASI: Stem cells are the wonder cells and there is a growing need to spread awareness about the importance of these cells to realise their

potential, says Dr CV Nerikar. Nerikar is the former blood transfusion officer, Nagpur Medical College, and the chief executive officer of the country’s only stem cell bank. He was speaking at a continuing medical education (CME) programme in the city on Sunday evening.

The programme was organised by Varanasi Obstetrics and Gynaecologists Society (VOGSI). As he stressed on the need to promote stem cell banking in the country, its advantages were also emphasised. “These cells are preserved at very low temperature (-196 degree Celsius) and can be used for nearly 130 years (two generations),” he said on the occasion.

“The stem cells have inherent capacity to multiply and regenerate into all specialised cells of the body and could be used in multiple life threatening diseases, including genetic disorders,” informed Dr Neriker. Stem cell transplant has successfully treated complicated and life threatening diseases including blood cancer (acute leukemia), thalassemia, blood disorders and other immune deficiencies. “Currently, stem cell research is also going on a number of diseases including spinal cord injury, cardiac diseases, diabetes and stroke,” he added.

He also said the umbilical cord blood is the easiest source of retrieving stem cells and the blood that is usually thrown as wastage should be preserved for complex diseases, especially for treating genetic disorders in the family.

President, VOGSI, Dr Amod Prakash and other senior obstetricians and gynaecologists were also present on the occasion.


NFCTR Receives $1.6 Million Grant for Cell Transplant Research

September 12, 2009

Courtesy by: marketwatch

LOUISVILLE, Ky., Sep 9, 2009 (GlobeNewswire via COMTEX) — The National Foundation to Support Cell Transplant Research (NFCTR) today announced that it has received $1.6 million in federal support for research and clinical trials it is funding at the University of Louisville. Congressman John Yarmuth (D-3rd District) secured the funds to support cell transplant technologies developed by Dr. Suzanne Ildstad and the Institute for Cellular Therapeutics at U of L as part of the 2009 U.S. Department of Defense Appropriations Bill.

Dr. Ildstad’s research, now in clinical trials at the University of Louisville, Duke University and Northwestern University, may make it possible to perform complex tissue transplants without the need for anti-rejection medication in the treatment of catastrophic burn and blast injuries. The research is also being applied in new treatments for autoimmune diseases such as multiple sclerosis and inherited disorders such as sickle cell disease and thalassemia.

“The NFCTR is one of the foremost research centers dedicated to advancing life-saving medical research technologies… technologies that are being developed right here in Louisville,” Yarmuth noted.

Translating scientific discoveries into clinical treatments is expensive, and there is often a gap in funding for early stage clinical trials. “We work to fund that gap,” states Dr. Paula Grisanti, Chair of the NFCTR. “We also support patients participating in early stage clinical trials who might otherwise need to fund their participation out of pocket.”

“We are a national non-profit foundation that raises funds to support adult stem cell research… and this appropriation is a great example of how public-nonprofit partnerships can work together to fund important medical research,” Dr. Grisanti adds. “We are very grateful to Congressman Yarmuth for his instrumental assistance in securing these federal funds in support of Dr. Ildstad’s research.”

About the National Foundation to Support Cell Transplant Research (NFCTR)

Formed in 2005, the National Foundation to Support Cell Transplant Research (NFCTR) was established to support peer-reviewed research and early stage clinical trials in the field of adult stem cell transplantation. Adult stem cell research has the potential to revolutionize the treatment of a large number of diseases and conditions affecting people worldwide. The NFCTR funds research in a number of strong academic settings and supports both collaboration and information sharing wherever possible. Through the funding of these collaborations, the NFCTR hopes to create stronger opportunities for advancements in the field. For more information, visit www.nfctr.org or call (502) 379-8544.


Grant to aid stem-cell research

September 1, 2009

Courtesy by: courier-journal

A University of Louisville Medical School program focusing on cell-transplant research is the recipient of a $1.6 million federal grant from the U.S. Department of Defense that U.S. Rep. John Yarmuth, D-3rd District, helped secure.

The funds will primarily go to support research into adult stem-cell transplant technology at U of L’s Institute of Cellular Therapeutics. The money will be passed through the National Foundation to Support Cell Transplant Research.

The institute’s director, Dr. Suzanne Ildstad, has made some major breakthroughs in bone-marrow transplant technology.

Her team’s discoveries have helped make it possible to safely transfer marrow from one person to another without life-threatening rejection. That holds the promise of permanently treating or curing autoimmune diseases and blood disorders affecting millions worldwide, officials said at a news conference Monday.

The new funding is critical to turning research findings into treatments for such conditions as sickle-cell disease, thalassemia, multiple sclerosis and other metabolic disorders, Ildstad said.

Yarmuth acknowledged that the funding through the 2009 Defense Department appropriations bill could be considered one of his earmarks. He said the Defense Department provided the funding, in part, because the research has implications in helping wounded soldiers, including those who have suffered spinal-cord injuries and those who have lost limbs.

Yarmuth said the funding is a recognition not only of the talented team Ildstad has assembled at U of L, but also of the progress that the team has made.

“They are on the verge of making some really important breakthroughs in areas that can offer a cure for diabetes and some of the other really stubborn medical problems we have. There’s really no limit to how important this research could end up being,” he said. “You’re talking about essentially saving hundreds of millions of dollars a year” in health care costs, “not to speak of the factor of changing lives.”

The Louisville-based National Foundation to Support Cell Transplant Research supports research in adult stem-cell transplantation at U of L as well as at Duke and Northwestern universities.

Ildstad said the institute research team includes a staff of about 55. The program was recruited to U of L from Philadelphia in 1998. Ildstad said the foundation was set up about three years ago and that some of the initial research was funded by a $2.5 million federal grant.

She said the research has also been supported by a variety of private donations to U of L. All of the research is being conducted at U of L, she said, while some of the applications of the research are being tried at medical facilities at the North Carolina and Illinois institutions.

As an example of the work, Ildstad said one recent case involved a boy in Louisville with sickle-cell disease who “could not go outside or play soccer” with other children. He received bone marrow from a sister, and he is now “growing like a weed” and leading a normal life, Ildstad said.

Officials said the new round of funding will go a long way toward advancing the research into adult stem-cell transplant technology.

Yarmuth’s success in obtaining the funding and the support of Dr. Paula Grisanti, chairwoman of the cell-transplant foundation, help researchers such as Ildstad “create the results that bring cures to people with what were seemingly incurable diseases,” U of L President James Ramsey said in a statement.


Cord blood bank to be set up in Ahmedabad

August 17, 2009

Courtesy by: indianexpress.com

A new collaboration between StemCyte Inc. of the US and Apollo Hospital Enterprises Ltd. now promises to bring about a revolution in the treatment about 70 diseases by introducing the ‘plasma depletion’ technology in India.

A Memorandum of Understanding between the two companies was signed at the Vibrant Gujarat Summit and the collaboration has resulted into StemCyte India Therapeutics Pvt. Ltd. This cord blood bank will be located in Ahmedabad and will have the patented technique of processing and storage of StemCyte Inc., announced the officials of the StemCyte on Thursday.

The technology of collecting high volume of stem cells called ‘plasma depletion’ which helps in successful therapeutic applications of umbilical cord stem cells can be used in the treatment of 70 different diseases like leukaemia, lymphoma, myeloma, thalassemia, sickle cell anaemia, fanconi anaemia and auto immune deficiency diseases. These diseases have been successfully treated with umbilical cord stem cells. The umbilical cord blood stem cells are fast emerging as a prime source of stem cells in the field of regenerative medicine, repair of injured tissues, nerves and organs.

According to Tushar Dalal, president of StemCyte India, the company plans to build 20,000 diverse units to help treat critically ill patients in India and abroad. He said, “Strategically situated in Gujarat, which has the highest frequency of Thalassemia patients, StemCyte India will spread the ray of hope among patients of this life threatening disease.”

While StemCyte has earlier signed two research and licensing agreements for human umbilical cord blood stem cell treatment of spinal cord injury, stroke, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, ALS, and other problems of the central nervous system, these research programs will be conducted in India by Apollo Hospitals and Cadila Pharmaceuticals here as well.


Cyrobanks aims to collect 20,000 samples nationally in a year

August 17, 2009

Courtesy by: indopia.in

Kochi , July 30 Cryobanks International India, a umbilical cord blood stem cell banking company, has set itself a target of collecting 20,000 samples nationally within a year, the company CEO C V Nerikar said today.
” Already 10,000 samples have been collected so far and another 10,000 would be collected in a year&aposs time,”he told reporters here.

The umbilical cord blood is a rich source of stem cells and the bank would help store them from any willing family for a certain fee, he said, adding that the cells would be vital in saving the lives of those suffering from leukaemia, thalassemia, blood cancer and those who need a bone marrow transplant.

The company started operations in Kerala in 2008,opening a branch at Thiruvananthapuram. It now also operates from Kochi , Thrissur and Kottayam. A unit in Kozhikode is also likely to come up.

At present there are 80 centres in India, from which 10,000 samples have been collected in the last two years, he said, adding that the company now has a presence in Tier II and Tier III cities and hopes to have centres in rural areas in a couple of years.